scuba wrote:
I am very puzzled that the CML specialists, when faced with myelosuppression in their patients, keep trying the high dose's with drug interuption rather than go the other way and see if response stabilizes at a low dose and then work up.
There is a great need to prevent myelosuppression from becoming "side effect". It's side effectiveness could render TKI not approved. It's why they try to call myelosuppression "an unfortunate consequence" of having CML and using TKIs, which actually makes your head hurt if you think about it too long. Espcially when people gain two pounds and the docs immediately change drugs and are pulling their hair out to solve this medical mystery, while people suffering through neupogen and the now other unknown leukemic world of chronic, apparent lifetime low anc get "unfortunate consequence" and that's just too bad.
That's my experience so far with my Mrs. I don't have evidence from anyone else to demonstrate any other conclusions. If anyone has some, please put it up here. Don't just call me a bitter kook without some explanation.
rct